Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study

Organizer:
Institute for Interdisciplinary Health Research (IIHR)
Project start date:
2020-05-05

This project aims to estimate the seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia. We have already conducted 5 rounds of serological survey. According to data collected in October 2021, 83% of St. Petersburg residents have SARS-CoV-2 antibodies.

Project News

83% of petersburgers have coronavirus antibodies

15.11.2021
According to the results of the new stage of a serological survey, more than 80% of adults in St. Petersburg have antibodies to SARS-CoV-2. Repeat infections (confirmed by PCR tests) are relatively rare events-under 3%. In order for the active phase of the epidemic to end, as many citizens as possible must have immune protection.

Публикации проекта

COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data

Author(s):

Anton Barchuk, Dmitriy Skougarevskiy, Alexei Kouprianov, Daniil Shirokov, Olga Dudkina, Rustam Tursun-zade, Mariia Sergeeva, Varvara Tychkova, Andrey Komissarov, Alena Zheltukhina, Dmitry Lioznov, Artur Isaev, Ekaterina Pomerantseva, Svetlana Zhikrivetskaya, Yana Sofronova, Konstantin Blagodatskikh, Kirill Titaev, Lubov Barabanova, Daria Danilenko

 

Year of publication:

This study summarises results from four consecutive serological surveys conducted between May 2020 and April 2021 at St. Petersburg, Russia and combines them with other SARS-CoV-2 surveillance data. 

Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study

Author(s):

Anton Barchuk, Dmitriy Skougarevskiy, Kirill Titaev, Daniil Shirokov, Yulia Raskina, Anastasia Novkunkskaya, Petr Talantov, Artur Isaev, Ekaterina Pomerantseva, Svetlana Zhikrivetskaya, Lubov Barabanova, Vadim Volkov

Тип издания:
Журнал
Year of publication:

This study aims to estimate the seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia accounting for non-response bias.

Evaluation of the performance of SARS-­CoV­-2 antibody assays for a longitudinal population­based study of COVID-­19 spread in St. Petersburg, Russia

Author(s):

Anton Barchuk, Daniil Shirokov, Mariia Sergeeva, Rustam Tursun­zade, Olga Dudkina, Varvara Tychkova, Lubov Barabanova, Dmitriy Skougarevskiy, Daria Danilenko

Тип издания:
Журнал
Year of publication:

This study summarizes an evaluation of antibody tests used in a serological study of SARS-­CoV­-2 in Saint Petersburg, Russia. Researches validated three different antibody assays: chemiluminescent microparticle immunoassay (CMIA) Abbott Architect SARS-­CoV­-2 immunoglobulin G (IgG), enzyme­ linked immunosorbent assay (ELISA) CoronaPass total antibodies test, and ELISA SARS­-CoV-­2-­IgG-­EIA-­BEST.